Summary of Evaxion Earnings Call (Q4 2025)

1Key Financial Results and Metrics

Cash Position: Ended 2025 with $23 million in cash, extending the cash runway into the second half of 2027.

Revenue: Improved revenue driven by MSD option exercises and a grant from the Gates Foundation.

Net Loss: Reported a net loss of $7.7 million, an improvement compared to the previous year.

Cash Inflows: Total cash inflow of $32 million from various financing activities, including public offerings and the exercise of investor warrants.

2Strategic Updates and Business Highlights

Partnerships: Successful collaboration with MSD, which exercised its option on the EVX-B3 program. Interest remains high for the EVX-B2 candidate, despite MSD not exercising its option.

R&D Progress: Positive Phase II data for the EVX-01 cancer vaccine presented at ESMO, showing a 75% objective response rate and a 25% complete response rate.

AI Immunology Platform: Recognition from the Galien Foundation for advancements in AI in human health. The platform continues to evolve, with new automated modules enhancing vaccine design efficiency.

New Initiatives: Exploration of autoimmune diseases as a new focus area, leveraging the AI platform for identifying targets.

3Forward Guidance and Outlook

2026 Milestones: Plans to update on EVX-01 with additional biomarker data, submit a regulatory application for EVX-04, and advance the EVX-B4 candidate in Group B strep.

Partnership Discussions: Ongoing discussions with potential partners for EVX-01 and EVX-B2, with a focus on showcasing the strength of the AI platform and clinical data.

4Bad News, Challenges, or Points of Concern

Partnership Setbacks: MSD chose not to exercise its option on the EVX-B2 candidate, which may indicate hesitance or the need for further validation.

Market Competition: The cancer vaccine space is highly competitive, with many companies pursuing similar targets, which could impact partnership opportunities.

Execution Risks: The need for further validation and data to attract partners for new candidates like EVX-04 highlights potential execution risks.

5Notable Q&A Insights

CEO Transition: Helen Tayton-Martin emphasized a focus on optimizing the value of existing assets and deepening engagement with partners.

EVX-01 Partnering: Interest from potential partners is driven by the strong clinical data and the unique approach to cancer antigens.

Autoimmune Focus: The company is in the early stages of identifying key autoimmune indications, with plans to leverage existing AI capabilities for new therapies.

Merck Collaboration: Discussion around Merck's decision to extend evaluation of EVX-B2 indicates ongoing R&D complexities and the need for additional data. Overall, Evaxion demonstrated significant operational progress in 2025, with a solid financial position and promising R&D advancements, while also facing challenges in partnership negotiations and competitive pressures in the biotech landscape.